home / stock / orpof / orpof short
Short Information | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 10,120 |
Total Actual Volume | 10,120 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 3 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 506 |
Average Short Percentage | 15.00% |
Is there a ORPOF Short Squeeze or Breakout about to happen?
See the ORPOF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
08-26-2019 | $4.00 | $4.00 | $4.00 | $4.00 | 120 | 120 | 100% |
06-13-2019 | $N/A | $4.75 | $N/A | $N/A | 5,000 | 5,000 | 100% |
04-04-2019 | $4.75 | $4.75 | $4.75 | $4.75 | 5,000 | 5,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
OTCMKTS Market:
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , nor the €5.8 million of R&D Tax credit, p...